期刊文献+

双氯芬酸钠缓释片预防紫杉醇所致的肌肉关节疼痛的临床研究 被引量:4

Diclofenac Sodium to Prevent Muscle and Joint Pain induced by Paclitaxel: A Clinical Trial
在线阅读 下载PDF
导出
摘要 目的:观察双氯芬酸钠缓释片在治疗紫杉醇所致的肌肉关节疼痛的作用。方法:收集2009年12月~2010年5月川北医学院附属医院肿瘤科使用紫杉醇化疗、发生肌肉关节疼痛的恶性肿瘤患者60例,采用对照研究分为两组:治疗组与对照组。治疗组:口服双氯芬酸钠;对照组:空白对照。按WH0推荐的抗癌药物不良反应分级(0级为无,Ⅰ级为轻度,Ⅱ级中度,Ⅲ级为重度,Ⅳ级为极重)标准评价不良反应。结果:治疗组治疗紫杉醇所致的肌肉关节疼痛,治愈率(0级)为35.0%,有效率(0级+Ⅰ级)为63.3%。结论:口服双氯芬酸钠缓释片减少紫杉醇所致的肌肉关节疼痛发生率,并不同程度地改善疼痛程度。 Objective: To evaluate the effect of diclofenac sodium on prevention of muscle and joint pain induced by paclitaxel. Methods: From Dec. 2009 to May 2010,60 patients received chemotherapy of paclitaxel were randomly divided into two groups: treatment and blank group. The patients in the treatment group received diclofenac sodium to prevent muscle and joint pain induced by paclitaxel, the patients in the blank group did not receive diclofenac sodium. Adverse reaction was evaluated according to WHO evaluation of adverse effect of medicine(0 ranking was none, 1 rank mild, 2 rank moderate, 3 rank severe, 4 rank extremelysevere). Results: Cure rate of diclofenac sodium for muscle and joint pain induced by paclitaxel was 35.0%, effective rate was 63.3% in treatment group. Conclusion : Diclofenac sodium can reduce the incidence and relief the degree of muscle and joint pain induced by paclitaxel.
出处 《肿瘤预防与治疗》 2010年第6期467-469,共3页 Journal of Cancer Control And Treatment
关键词 双氯芬酸钠 紫杉醇 肌肉关节疼痛 Diclofenac Sodium Paclitaxel Muscle and Joint Pain
作者简介 侯敏(1982-),女,四川平武人,医师,硕士研究生,主要从事肿瘤放化疗,肿瘤综合治疗工作。 [通讯作者]谭榜宪,教授,硕士生导师。
  • 相关文献

参考文献18

  • 1Horwitz SB.Mechanism of action of taxol[J].Trends Pharmacol Sci,1992,13 (4):134-136.
  • 2Stierle A,Strobel G,Stierle D,et al.The search for a taxol-producing microorganism among the endophytic fungi of the Pacific yew,Taxus brevifolia[J].J Nat Prod,1995,58(9):13-15.
  • 3Byrd CA,Bornmann W,Erdjument-B romage H,et al.Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide[J].Proc Natl Acad Sci USA,1999,96 (10):5645.
  • 4Srivastava RK,Sasaki CY,Hardwick JM,et al.Bcl-2-mediated drug resistance:Inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription[J].J Exp Med,1999,190 (2):253.
  • 5Kluber N,Parangi S,Flynn E,et al.Inhibition of angiogensis and breast cancer in mice by the microtubule inhibition I-me-thoxyestradionl and Paclitaxel[J].Cancer Res,1997,57(1):81-82.
  • 6梅兴国,鲁明波.紫杉醇的抗癌作用及治疗其他疾病的潜力[J].国外医学(药学分册),1996,23(3):136-140. 被引量:35
  • 7Downs Ls Jr,Judson PL,Argenta PA,et al.A phase I study ofifosfamide,paclitaxe,and carboplatin in advanced and recurrent cervical cancer[J].Gynecol Oncol,2003,95 (2):347-351.
  • 8Davidson NG.Single-agent paclitaxel as first line treatment of metastatic breast cancer:The B ritish experience[J].Semin-Oncol,1996,23 (5):6.
  • 9张力,姜文奇,徐瑞华,管忠震.紫杉醇(Paclitaxel)治疗晚期鼻咽癌的临床研究[J].癌症,2000,19(8):811-813. 被引量:58
  • 10Szebeni J,Muggia FM,Alving CR.Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel:An in vitro study[J].J Natl Cancer Inst,1998,90(4):300.

二级参考文献41

共引文献194

同被引文献42

  • 1陈东升,吴光兴,唐丽珠.胰腺癌根治术后行吉西他滨联合替吉奥化疗的临床观察[J].实用癌症杂志,2014,29(1):78-80. 被引量:19
  • 2丁雷,张平.胰腺癌治疗的研究进展[J].中国老年学杂志,2014,34(8):2298-2300. 被引量:33
  • 3王彦,王子轩,刘志梅.对肝癌介入治疗中疼痛患者进行心理干预的效果分析[J].中华护理杂志,2007,42(5):424-426. 被引量:66
  • 4Benedet JL, Bender H, Jones HR, et al. FIGO staging classifica- tions and clinical practice guidelines in the management of gyneco- logic cancers. FIGO Committee on Gynecologic Oncology[ J]. Int J Gynaecol Obstet,2000,70 ( 2 ) : 209 - 262.
  • 5Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Or- ganization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [Jl. JNatlCancerlnst,2000,92(3):205-216.
  • 6Aoki Y, Sato T, Watanabe M, et al. Neoadjuvant chemotherapy using low - dose consecutive intraarterial infusions of cisplatin combined with 5 - fluorouracil for locally advanced cervical adeno- carcinoma[ J]. Gynecol Oncol,2001,81 ( 3 ) :496 - 499.
  • 7Onishi H, Yamaguchi M, Kuriyama K, et al. Effect of concurrent intra - arterial infusion of platinum drugs for patients with stage Ⅲ or Ⅳ uterine cervical cancer treated with radical radiation ther- apy[J]. Cancer J Sci Am,2000,6(1) :40 -45.
  • 8Homesley HD, Meltzer NP, Nieves L, et al. A phase Ⅱ trial of weekly 1 - hour paclitaxelas second - line therapy for endometrial and cervical cancer [ J ]. Int J Clin 0ncol,2008,13 ( 1 ) :62 - 65.
  • 9Secord AA, Havrilesky LJ, Carney ME, et al. Weekly low - dose paclitaxel and carboplatin in the treatment of advanced or recurrlnnt cervical and endometrial cancer [ J]. Int J Clin 0ncol,2007,12 (1) :31 -36.
  • 10Ueno H, Ioka T, Ikeda M, et al. Randomized phase II1 study of gemcitabine plus S-1,S-I alone,or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013, 31(13):1640-1648.

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部